Sub-retinal implant
Colin Kerr
Published: Wednesday, November 1, 2017
Pixium Vision has announced that its next-generation miniaturised wireless sub-retinal implant, PRIMA, has received authorisation from the French regulatory agency, Agence nationale de sécurité du médicament et des produits de santé (ANSM), to start a feasibility clinical study in patients with advanced dry age-related macular degeneration (dry-AMD).
Khalid Ishaque, Chief Executive Officer of Pixium Vision, a company developing bionic vision systems to enable patients who have lost their sight to lead more independent lives, commented: “PRIMA enters an exciting phase of its development, with a first patient expected to be implanted before year end.”
www.pixium-vision.com
Tags: sub-retinal implant
Latest Articles
Glaucoma Treatment Under Pressure
New techniques and technologies add to surgeons’ difficult decisions
Outside the Box, Inside the Pipeline
Researchers are tackling glaucoma diagnosis and treatment from all sides.
The EHDS Is Ready for the Green Light
If proposal is approved, Europe could see better access to, and exchange and use of, health data.
ESCRS to Release Guidelines for Cataract and Refractive Surgery
Comprehensive approach to the safest and most effective modern surgery.
Barry Fellowship Opens Up ‘Whole New Field of Thought’
The 2022 recipient combines theoretical and practical to learn new treatments.
Digitalising the OR—Experience and Perspectives
Benefits include saving time and improving outcomes.
Dynamic Measures Needed for Quality of Vision
Functional visual acuity testing and straylight metering may better reflect real-world conditions.
What Is Stopping Digital OR Adoption?
Ophthalmologists know the benefits—now it’s time to construct the right plan.
Time to Move Beyond Monofocal IOLs?
European surgeons appear hesitant to first offer other presbyopia-correcting options to patients.